CLL Treatment Evolution

CE / CME

Evolving CLL Treatment Recommendations

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: October 06, 2022

Expiration: October 05, 2023

Activity

Progress
1
Course Completed

In this focused activity, Nicole Lamanna, MD; Nichole Fisher, RN, BSN; and Anthony Perissinotti, PharmD, BCOP, discuss how treatment for chronic lymphocytic leukemia (CLL) has evolved rapidly during the past 5 years and how this has affected clinical practice, with case studies used to illustrate current therapeutic paradigms.

Clinical Care Options (CCO) plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once before the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with CLL do you provide care for in a typical month?

An 80-year-old male with previously untreated CLL arrives in your care. He has bulky 7 x 7 cm bilateral axillary lymph nodes and 12 x 12 cm retroperitoneal and para-aortic nodes, along with significant chest lymphadenopathy. Worsening symptomatic anemia is observed, with a hemoglobin of 8.9 g/dL. He has no evidence of hemolysis, and his platelet level is 90 K/µL with a white blood cell level of 325 K/µL. Testing reveals his CLL to be IGHV unmutated, with normal fluorescence in situ hybridization (FISH). He has a long-standing history of controlled hypertension and diabetes; he also has chronic renal insufficiency with a creatinine of 2.0 mg/dL.

In your current practice, which of the following treatment options would you consider to be the optimal choice for this patient?